Risk Tolerance Study Pat Furlong, BSN, MS Holly Peay, MS CGC Vice - - PowerPoint PPT Presentation

risk tolerance study
SMART_READER_LITE
LIVE PREVIEW

Risk Tolerance Study Pat Furlong, BSN, MS Holly Peay, MS CGC Vice - - PowerPoint PPT Presentation

Treatment Preferences and Risk Tolerance Study Pat Furlong, BSN, MS Holly Peay, MS CGC Vice President, Education and Outreach ParentProjectMD.org Study Goals Objective: explore how parents/guardians of individuals with DMD prioritize risk


slide-1
SLIDE 1

ParentProjectMD.org

Treatment Preferences and Risk Tolerance Study

Pat Furlong, BSN, MS Holly Peay, MS CGC Vice President, Education and Outreach

slide-2
SLIDE 2

ParentProjectMD.org

Study Goals

  • Objective: explore how parents/guardians of

individuals with DMD prioritize risk and benefit in the context of new therapies

  • Specific Aims:

– Describe risk tolerance, health-related QoL, and numeracy – Explore treatment preferences, risk tolerance and benefit priorities – Evaluate the effect of child’s disorder progression on treatment preferences – Explore Duchenne-related worries

slide-3
SLIDE 3

ParentProjectMD.org

Methodology

  • Developed in consultation with health economist
  • Best/worst scaling type 2
  • “BWS is a theory about how people make best

and worst (most and least, smallest and largest, two extremes, etc.) choices from choice sets consisting of three or more ‘things’.” (Louviere and

Flynn 2010)

  • Based on random utility theory- value

respondent derives from an object compared with a comparator is proportional to how often he/she chooses it in preference to comparator

slide-4
SLIDE 4

ParentProjectMD.org

Attribute Development: Worries

  • 5 parents contributed a broad list of DMD-

related worry items

  • Researchers refined the items and grouped

under domains

  • Final worry domains

– child-focused (health, QoL, and social support) – external to the child (parent/guardian QoL, social support, family effects)

slide-5
SLIDE 5

ParentProjectMD.org

Attribute Development: Treatments

  • Large pool of hypothetical attributes and

levels identified in consultation with parents, providers, and biotech/pharma

  • Items reduced and refined during the

stakeholder consultation

  • Identified plausible attributes that are

sufficiently balanced to allow a successful experiment

slide-6
SLIDE 6

ParentProjectMD.org

Refinement and Piloting

  • Draft instruments refined in consultation

with social scientists with expertise in clinical research and rare disorder populations

  • Survey instrument piloted by 7 parents

who provided extensive feedback on the items and instrument as a whole

  • Final survey developed and implemented
  • nline
slide-7
SLIDE 7

ParentProjectMD.org

Worry List: In the past 7 days, most/least worried…

A My child missing out on new treatments B My child getting weaker C Getting the right care for my child over time D My child feeling happy E My child having good friends F My child feeling like a burden on the family G My child becoming independent from me over time H My child not being able to express deep worries J Being a good enough parent for my child K Me handling the emotional demands of Duchenne L Managing my uncertainty about my child’s future M Having time for myself N Feeling isolated from other families P Affording care my child needs within the family budget Q Effects of Duchenne on my closest relationships R The wellbeing of my other children

slide-8
SLIDE 8

ParentProjectMD.org

Treatment Attributes

LABEL EXPERIMENT DESCRIPTION A1 Muscle function Stops the progression of weakness A2 Muscle function Slows the progression of weakness A3 Muscle function Does not change progression of weakness B1 Lifespan 5 year gain in expected lifespan B2 Lifespan 2 year gain to expected lifespan B3 Lifespan No extra gain to expected lifespan C1 Drug knowledge 2 years of post-approval drug information available C2 Drug knowledge 1 year of post-approval drug information available C3 Drug knowledge No post-approval drug information available

slide-9
SLIDE 9

ParentProjectMD.org

Treatment Attributes Con’t

Label Experiment description D1 Nausea No increased chance of nausea D2 Nausea Causes loss of appetite D3 Nausea Causes loss of appetite with occasional vomiting E1 Bleeds No increased risk of bleeds E2 Bleeds Increased risk of bleeding gums and increased bruising E3 Bleeds Increased risk of hemorrhagic stroke and lifelong disability F1 Arrhythmia No increased risk of heart arrhythmia F2 Arrhythmia Increased risk of harmless heart arrhythmia F3 Arrhythmia Increased risk of dangerous heart arrhythmia and sudden death

slide-10
SLIDE 10

ParentProjectMD.org

Inclusion Criteria & Recruitment

  • Recruited from PPMD, DuchenneConnect

Registry, and snowball recruiting

  • Parents or guardians of at least one living

child with Duchenne muscular dystrophy, living in the United States, over 18 years

  • f age, and able to complete an online

survey in English

  • Study determined to be exempt by the

Western Institutional Review Board

slide-11
SLIDE 11

ParentProjectMD.org

Survey Components

  • Treatment experiment: 18 treatment scenarios
  • Worries experiment: 16 worries lists
  • Risk Taking Measure (Pearson et al.,1995): 6

items from the Jackson Personality Index

  • Numeracy (Fagerlin et al., 2007) 3 items

adapted from Subjective Numeracy Scale

  • SF-12 Health-Related QoL
  • Child DMD status (mobility and self-care PROM)
  • Care/support items
  • Demographics
slide-12
SLIDE 12

ParentProjectMD.org

Design

  • Detailed description of attributes and levels;

example task

  • 18 treatment choice tasks generated from

Youden design assessing the best and worst attribute

– Each treatment scenario followed by acceptability question (“If this treatment were real, would you use it for your child?”)

  • 16 worry choice tasks assessing the most and

least significant worries over the past 7 days

slide-13
SLIDE 13

ParentProjectMD.org

Experiment Example

Choose the best thing by clicking the circle under “best” and choose the worst thing by clicking the circle under “worst.” You have to choose a best thing and a worst thing to move on. Remember that a computer chose combinations to make the experiment work, and some of them seem bad. Even so, please pick the best and worst thing.

slide-14
SLIDE 14

ParentProjectMD.org

Preliminary Analysis

  • Level utility scores (across all choice sets

and respondents)

– # of times attribute level chosen worst - # of times chosen best/# times attribute appears in experiment*# participants

  • Attribute importance scores

– Max level mean - min level mean/total of all attribute max-min means

  • Multinomial analysis ongoing
slide-15
SLIDE 15

ParentProjectMD.org

Preliminary Results

  • 119 parents completed entire survey
  • Mean participant age 43.7 (SD 7.7)
  • Mean affected child age 12.1 (SD 6.4)
  • 80 (67%) biological mothers, 34 (29%)

biological fathers, 5 (4%) adoptive parents

  • 109 (92%) Caucasian
  • 107 (90%) married, 11 (9%)

divorced/separated, and 1 (1%) widowed

slide-16
SLIDE 16

ParentProjectMD.org

  • 6. What is your annual household income?

Frequency % Valid % Less than $25,000 7 5.9 6.0 $25,000-$50,000 10 8.4 8.5 $50,000-$75,000 22 18.5 18.8 $75,000-$100,000 22 18.5 18.8 More than $100,000 56 47.1 47.9 Total 117 98.3 100.0 System 2 1.7 Total 119 100.0

slide-17
SLIDE 17

ParentProjectMD.org

  • 5. What is the highest level of education you have completed?

Freq % Valid % High school or GED 5 4.2 4.2 Some college but no degree 17 14.3 14.4 Technical school 6 5.0 5.1 Associate’s degree (2-year college degree) 9 7.6 7.6 4-year college degree (e.g., BA, BS) 44 37.0 37.3 Some graduate school but no degree 7 5.9 5.9 Graduate or professional degree (e.g., MBA, MS, MD, PhD) 30 25.2 25.4 Total 118 99.2 100.0 System 1 .8 Total 119 100.0

slide-18
SLIDE 18

ParentProjectMD.org

Affected Children

  • 110 (92%) have one affected child; 9 (8%)

have two or more affected children

  • 101 (85%) have private insurance; 40

(34%) have a state/government program

  • 68 (58%) participated in clinical research

and 40 (34%) participated in a clinical trial

  • 22 (19%) child has experienced a life-

threatening emergency that caused parent to worry that the child would die

slide-19
SLIDE 19

ParentProjectMD.org

  • 4. Chose the option that best describes your child’s physical abilities today.

Frequency % Is a baby, a toddler, or a very young child who is too young to walk far yet 5 4.2 Walks independently for long distances outdoors (more than ½ mile) 24 20.2 Walks less than ½ mile, but more than short distances 35 29.4 Walks independently outdoors for short distances (such as to the car) 12 10.1 Walks outdoors with help from a person 1 .8 Walks independently indoors but needs a wheelchair for outdoors 2 1.7 Walks indoors with help from a person and requires wheelchair

  • utdoors

4 3.4 Uses wheelchair and can go indoors and outdoors 30 25.2 Uses wheelchair but unable to go outdoors in some situations (such as cold weather) 3 2.5 Unable to control wheelchair without help 3 2.5 Total 119 100.0

slide-20
SLIDE 20

ParentProjectMD.org

Preliminary Conclusions

Within the context our experiment:

  • Worries related to child’s illness progression and

care accounted for the largest proportion of the variance in the worries attributes.

  • Stopping or slowing the progression of muscle

weakness accounted for the largest proportion

  • f the variation in treatment attributes.

Our evidence suggests that the presence of side effects/risks could be compensated for by a treatment that stops progression to muscle function.

slide-21
SLIDE 21

ParentProjectMD.org

Next Steps

  • Further analysis ongoing
  • Seeking input from FDA about

acceptability and interest

  • Possible refinement and second survey
  • Focus groups/community input
  • “Tell Your Story” open-ended data

collection and analysis ongoing

slide-22
SLIDE 22

ParentProjectMD.org

Collaborators

  • John Bridges, PhD, Department of Health

Policy and Management, Johns Hopkins Bloomberg School of Public Health

  • Ilene Hollin, Department of Health Policy

and Management, Johns Hopkins Bloomberg School of Public Health

  • Sharon Hesterlee, PhD, PPMD
  • Hadar Sheffer, MPH, PPMD